Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence using a Novel Regenerative Cell Therapy
Zurich, Switzerland, September 8, 2022 -- Muvon Therapeutics AG, an innovative clinical-stage biotechnology company announced results from a Phase I clinical trial. This first study evaluating a proprietary cell therapy platform demonstrated the safety, feasibility and potential efficacy of autologous skeletal muscle injections into the bladder sphincter of women suffering from Stress Urinary Incontinence with the goal of naturally restoring strength and function over 6 months.Stress Urinary Incontinence (SUI) is defined as the complaint of any involuntary loss of urine on effort or